Targeting the tumor stroma for cancer therapy

M Xu, T Zhang, R Xia, Y Wei, X Wei - Molecular Cancer, 2022 - Springer
Tumors are comprised of both cancer cells and surrounding stromal components. As an
essential part of the tumor microenvironment, the tumor stroma is highly dynamic …

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

Z Zhang, X Liu, D Chen, J Yu - Signal Transduction and Targeted …, 2022 - nature.com
Radiotherapy (RT) is delivered for purposes of local control, but can also exert systemic
effect on remote and non-irradiated tumor deposits, which is called abscopal effect. The view …

Type I interferon-mediated tumor immunity and its role in immunotherapy

R Yu, B Zhu, D Chen - Cellular and Molecular Life Sciences, 2022 - Springer
Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses
in patients with many different types of cancer; however, most patients who receive ICB …

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

H Zhang, X Yue, Z Chen, C Liu, W Wu, N Zhang, Z Liu… - Molecular Cancer, 2023 - Springer
Despite centuries since the discovery and study of cancer, cancer is still a lethal and
intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much …

The Notch signaling pathway: a potential target for cancer immunotherapy

X Li, X Yan, Y Wang, B Kaur, H Han, J Yu - Journal of hematology & …, 2023 - Springer
Dysregulation of the Notch signaling pathway, which is highly conserved across species,
can drive aberrant epigenetic modification, transcription, and translation. Defective gene …

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

FGO Kurt, S Lasser, I Arkhypov, J Utikal… - The Journal of …, 2023 - Am Soc Clin Investig
Despite the remarkable success of immune checkpoint inhibitors (ICIs) in melanoma
treatment, resistance to them remains a substantial clinical challenge. Myeloid-derived …

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

JL Vos, B Burman, S Jain, CWR Fitzgerald… - Nature medicine, 2023 - nature.com
Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments
when metastasized. We conducted a phase 2 trial evaluating nivolumab (nivo, anti-PD-1) …

Exploiting innate immunity for cancer immunotherapy

M Yi, T Li, M Niu, Q Mei, B Zhao, Q Chu, Z Dai, K Wu - Molecular cancer, 2023 - Springer
Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

A Microenvironment Dual‐Responsive Nano‐Drug Equipped with PD‐L1 Blocking Peptide Triggers Immunogenic Pyroptosis for Prostate Cancer Self‐Synergistic …

H Wang, Z Gao, D Jiao, Y Zhang… - Advanced Functional …, 2023 - Wiley Online Library
Induction of immunogenic cell death (ICD) in tumor combined with immune checkpoint
blockade (ICB) therapy is widely developed to improve the efficacy of cancer …

STAT3 pathway in cancers: Past, present, and future

HQ Wang, QW Man, FY Huo, X Gao, H Lin, SR Li… - MedComm, 2022 - Wiley Online Library
Signal transducer and activator of transcription 3 (STAT3), a member of the STAT family,
discovered in the cytoplasm of almost all types of mammalian cells, plays a significant role in …